Compare CENX & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | SDGR |
|---|---|---|
| Founded | 1995 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.3B |
| IPO Year | 1996 | 2020 |
| Metric | CENX | SDGR |
|---|---|---|
| Price | $31.43 | $18.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $33.00 | $26.57 |
| AVG Volume (30 Days) | ★ 1.9M | 776.3K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,525,100,000.00 | $256,951,000.00 |
| Revenue This Year | $16.07 | $23.69 |
| Revenue Next Year | N/A | $20.46 |
| P/E Ratio | $37.84 | ★ N/A |
| Revenue Growth | 20.15 | ★ 32.90 |
| 52 Week Low | $13.05 | $15.99 |
| 52 Week High | $34.52 | $28.47 |
| Indicator | CENX | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 50.16 |
| Support Level | $29.30 | $17.53 |
| Resistance Level | $32.13 | $18.28 |
| Average True Range (ATR) | 1.23 | 0.66 |
| MACD | 0.29 | 0.20 |
| Stochastic Oscillator | 75.21 | 66.25 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.